Alvin Wells, MD, PhD, and Jorge Larranaga, MD, highlight the goals of treatment for patients with lupus nephritis.
Jorge Larranaga, MD: The goals of therapy for patients with lupus nephritis have changed over time. Based on the MAINTAIN trial in 2016, we know protein reduction is critical for long-term renal outcome. Therefore, prompt diagnosis, biopsies, and therapeutic interventions are important for these patients in focusing on reducing proteinuria, obtaining a bland urinalysis, and trying to get the urine PCR [protein-creatinine ratio] less than 700 mg/g, depending on what you read, or less than 500 mg/g, depending on the study.
We have lacked data in academic research for over 40 years regarding the management of lupus nephritis. The lack of data has left us with a status quo of partial remission—in essence, having patients with protein leakages greater than 1.5 g or above. We often relied on a 50% reduction, which we clearly know based on the data hasn’t been sufficient to treat these patients to a complete remission. Depending on the articles you read, complete remissions and partial remissions are varied. But overall, the consensus is that if we’re able to get a protein excretion less than 700 mg per day, those patients do quite well with less deterioration from a renal perspective in outcome.
We also know the European guidelines have been well defined and accepted by the US guidelines, where the reduction of urine PCR with the standard of therapy of blood pressure control, RAS blockade, etc, has led to the backbone of management of these patients along with the standard of care that has been set forward. Dr [Gerald] Appel, Dr [Gabriel] Contreras from the University of Miami, and other colleagues [showed the value of] MMF [mycophenolate mofetil]–Cytoxan therapy and steroid therapies, which were the standard of therapy for many years until 2020. We now have 2 medications with good outcomes that we’re able to add to the revolver and treat the complexity of these patients that we haven’t had in 40 years.
Alvin Wells, MD, PhD: I tell my patients with lupus nephritis that we need to set some goals. I sit down with them and ask, “What are your goals? What do you want to do?” They say, “Dr Wells, I don’t want to have pain or fatigue. I don’t want the swelling in my ankles to continue.” As a rheumatologist, I want to make sure your disease is under control, that you don’t get end-stage kidney disease and end up on dialysis. We try to put those features together. Even though we talk about kidney disease, some of the biggest things that drive patients into the clinic are swelling of their ankles, weight gain, and fatigue. These patients might go to bed at night and think they’re sleeping for 6 or 7 hours, but when they wake up, they feel like they’ve been hit by a truck. That’s because the immune system is turning like a machine and not able to shut off unless we use aggressive medications.
With patients with lupus and lupus nephritis, I say “Let’s talk about our goals.” Let’s see if I can minimize certain drugs, such as corticosteroids, which have some adverse effects we don’t like for long-term [use]. Let’s see if we can maximize and preserve their kidney function long term so that a 30-year-old woman who presents with lupus nephritis can have as close to a normal life expectancy as possible.
Transcript edited for clarity.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Valoctocogene Roxaparvovec Dramatically Reduces Bleeding in Hemophilia A
May 15th 2024New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.
Read More